Complex Operative Unit of Hematology

Bari, Italy

Complex Operative Unit of Hematology

Bari, Italy
SEARCH FILTERS
Time filter
Source Type

Mazza P.,Complex Operative Unit of Hematology ASL | Specchia G.,Complex Operative Unit of Hematology | Di Renzo N.,Complex Operative Unit of Hematology ASL | Cascavilla N.,Unit of Hematology and Bone Marrow Transplantation Casa Sollievo Della Sofferenza' S. Giovanni Rotondo | And 9 more authors.
Leukemia and Lymphoma | Year: 2016

We evaluated ruxolitinib in 65 patients with myelofibrosis according to age, sex, time of diagnosis, grade of fibrosis, prognostic score risk, Janus kinase (JAK) status, primary or secondary myelofibrosis, previous treatment, and dosage. Outcome measures were response rate, time to response, duration of response, and event-free survival and survival. Kaplan and Meier curves show a significant difference in event-free survival according to the prognostic score, in favor of patients with low int1 (p = 0.0009). The Cox stepwise model confirmed the result, the int2 high-risk score being the most powerful negative independent parameter (0.001), followed by JAK (0.008); other parameters, such as diagnosis more than 5 years earlier, grade III–IV fibrosis, and ruxolitinib dose have a negligible impact. Time to response was shorter (p = 0.001) in primary myelofibrosis. In conclusion, ruxolitinib is effective, with a better outcome in patients with a low-int1 risk score. This may suggest considering an earlier administration in the disease course. © 2016 Informa UK Limited, trading as Taylor & Francis Group


PubMed | D Unit Of Hematology And Bone Marrow Transplantation Casa Sollievo Della Sofferenza S Giovanni Rotondo, c Complex Operative Unit of Hematology ASL, f Complex Operative Unit of Hematology, e Complex Operative Unit of Hematology ASL BAT Andria and 2 more.
Type: Journal Article | Journal: Leukemia & lymphoma | Year: 2016

We evaluated ruxolitinib in 65 patients with myelofibrosis according to age, sex, time of diagnosis, grade of fibrosis, prognostic score risk, Janus kinase (JAK) status, primary or secondary myelofibrosis, previous treatment, and dosage. Outcome measures were response rate, time to response, duration of response, and event-free survival and survival. Kaplan and Meier curves show a significant difference in event-free survival according to the prognostic score, in favor of patients with low int1 (p=0.0009). The Cox stepwise model confirmed the result, the int2 high-risk score being the most powerful negative independent parameter (0.001), followed by JAK (0.008); other parameters, such as diagnosis more than 5 years earlier, grade III-IV fibrosis, and ruxolitinib dose have a negligible impact. Time to response was shorter (p=0.001) in primary myelofibrosis. In conclusion, ruxolitinib is effective, with a better outcome in patients with a low-int1 risk score. This may suggest considering an earlier administration in the disease course.


PubMed | Complex Operative Unit of Hematology and University of Bari
Type: | Journal: Journal of neuroimmunology | Year: 2017

We investigated, lymphocyte count (LC) and lymphocyte subpopulations (LS) in a real life setting of Fingolimod (FTY) treated Relapsing MS (RMS) patients. Peripheral blood counts with LS, relapses and MRI scans were recorded in a cohort of 119 FTY patients, during one year of treatment. Simple and multivariate logistic regression models, were performed. ROC analysis identified cut-off values of LS predicting a higher risk of relapses and of Gd+ lesions. We demonstrated a FTY-induced re-modulation of the immune system, suggesting that LS in RMS FTY treated patients can predict the clinical response to the drug.


PubMed | Ospedale Ss. Giovanni e Paolo and Complex Operative Unit of Hematology
Type: | Journal: Adolescent health, medicine and therapeutics | Year: 2017

About one-half of all Burkitt lymphoma (BL) patients are younger than 40 years, and one-third belong to the adolescent and young adult (AYA) subset, defined by an age between 15 and 25-40 years, based on selection criteria used in different reports. BL is an aggressive B-cell neoplasm displaying highly characteristic clinico-diagnostic features, the biologic hallmark of which is a translocation involving immunoglobulin and

Loading Complex Operative Unit of Hematology collaborators
Loading Complex Operative Unit of Hematology collaborators